Terms: = Leukemia AND EML4, ENSG00000143924, 27436 AND Treatment
11 results:
1. From 'Targeted Therapy' to Targeted Therapy.
Peters GJ
Anticancer Res; 2019 Jul; 39(7):3341-3345. PubMed ID: 31262854
[TBL] [Abstract] [Full Text] [Related]
2. eml4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.
Vargas-Madueno F; Gould E; Valor R; Ngo N; Zhang L; Villalona-Calero MA
Oncologist; 2018 Oct; 23(10):1127-1132. PubMed ID: 29739898
[TBL] [Abstract] [Full Text] [Related]
3. Analysis of ERBB ligand-induced resistance mechanism to crizotinib by primary culture of lung adenocarcinoma with eml4-ALK fusion gene.
Kimura M; Endo H; Inoue T; Nishino K; Uchida J; Kumagai T; Kukita Y; Kato K; Imamura F; Inoue M
J Thorac Oncol; 2015 Mar; 10(3):527-30. PubMed ID: 25695223
[TBL] [Abstract] [Full Text] [Related]
4. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract] [Full Text] [Related]
5. Secondary eml4-ALK-positive lung adenocarcinoma in a patient previously treated for acute lymphoblastic leukemia in childhood: a case report.
Nakamura Y; Taniguchi H; Mizoguchi K; Ikeda T; Motoshima K; Yamaguchi H; Nagashima S; Nakatomi K; Soda M; Mano H; Kohno S
Jpn J Clin Oncol; 2014 Jun; 44(6):593-6. PubMed ID: 24688086
[TBL] [Abstract] [Full Text] [Related]
6. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Pritchard CC; Salipante SJ; Koehler K; Smith C; Scroggins S; Wood B; Wu D; Lee MK; Dintzis S; Adey A; Liu Y; Eaton KD; Martins R; Stricker K; Margolin KA; Hoffman N; Churpek JE; Tait JF; King MC; Walsh T
J Mol Diagn; 2014 Jan; 16(1):56-67. PubMed ID: 24189654
[TBL] [Abstract] [Full Text] [Related]
7. Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Ong FS; Das K; Wang J; Vakil H; Kuo JZ; Blackwell WL; Lim SW; Goodarzi MO; Bernstein KE; Rotter JI; Grody WW
Expert Rev Mol Diagn; 2012 Jul; 12(6):593-602. PubMed ID: 22845480
[TBL] [Abstract] [Full Text] [Related]
8. Recent developments and future perspectives of personalized oncology.
Grüllich C; von Kalle C
Onkologie; 2012; 35 Suppl 1():4-7. PubMed ID: 22286581
[TBL] [Abstract] [Full Text] [Related]
9. Drug development: portals of discovery.
Bates SE; Amiri-Kordestani L; Giaccone G
Clin Cancer Res; 2012 Jan; 18(1):23-32. PubMed ID: 22215903
[TBL] [Abstract] [Full Text] [Related]
10. Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients.
Petrelli F; Borgonovo K; Cabiddu M; Ghilardi M; Barni S
Curr Med Chem; 2011; 18(11):1640-50. PubMed ID: 21428883
[TBL] [Abstract] [Full Text] [Related]
11. [Implications of ALK (anaplastic lymphoma kinase) in oncohematology].
Cluzeau T; Pécuchet N; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):991-6. PubMed ID: 20483705
[TBL] [Abstract] [Full Text] [Related]
